Pharmacological treatment of heart failure with preserved ejection fraction: a glimpse of light at the end of the tunnel? (Q44689964)

5 December 2017

0 references

Pharmacological treatment of heart failure with preserved ejection fraction: a glimpse of light at the end of the tunnel? (English)

1 reference

Heart failure with preserved ejection fraction

5 December 2017

1 reference

1 reference

Dirk J van Veldhuisen

series ordinal

1

object named as

Dirk J van Veldhuisen

1 reference

5 December 2017

2

John J V McMurray

1 reference

5 December 2017

28 November 2012

1 reference

European Journal of Heart Failure

5 December 2017

1 reference

5 December 2017

15

1 reference

5 December 2017

1

1 reference

5 December 2017

5-8

1 reference

Epidemiology and clinical course of heart failure with preserved ejection fraction

5 December 2017

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Heart failure with normal left ventricular ejection fraction: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Trends in prevalence and outcome of heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Comparing new onset heart failure with reduced ejection fraction and new onset heart failure with preserved ejection fraction: an epidemiologic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Irbesartan in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

The future diagnosis of heart failure with normal ejection fraction: less imaging, more biomarkers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Fail

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS194

21 January 2018

Identifiers

DOI

10.1093/EURJHF/HFS194

1 reference

5 December 2017

1 reference

PubMed ID

23193144